857-P: Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes—An Observational Study (PAUSE)

Introduction 0.0001; Fig.). Mean changes in weight and BMI were numerically greatest in subgroup 3 (Fig.). The proportion of patients with obesity (BMI ≥30 kg/m2) significantly decreased from 84.0% at baseline to 77.1% post-index (p0.0001). Conclusion: Adults with T2D initiating sema OW had statistically significant decreases in weight, BMI and HbA1c after 1 year, with better weight outcomes in patients persistent to treatment and receiving maintenance dose ≥1 mg. Disclosure J. Amamoo: None. R.P. Doshi: None. J. Noone: Employee; Novo Nordisk. L. Xie: None. C.L. Gamble: Employee; Novo Nordisk. M. Guevarra: Stock/Shareholder; Novo Nordisk. V. Divino: Employee; IQVIA Inc. J. Chen: None. A.A. King: Speaker's Bureau; Abbott, MannKind Corporation, Novo Nordisk. Advisory Panel; Novo Nordisk. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Lilly Diabetes. Speaker's Bureau; Dexcom, Inc. Advisory Panel; Dexcom, Inc. Speaker's Bureau; Astellas Pharma Inc. Funding Novo Nordisk